[8-K] Biofrontera Inc. Warrants Reports Material Event
Biofrontera Inc. furnished a press release announcing its financial and operational results for the three and six months ended June 30, 2025. The press release is furnished as Exhibit 99.1 and the Company states it includes non-GAAP financial measures with quantitative reconciliations to the most directly comparable GAAP measures in accordance with Regulation G. The filing explicitly notes this information is being furnished rather than filed and therefore is not subject to Section 18 liability nor automatically incorporated by reference in registration statements. The Form 8-K also identifies the registrant as an emerging growth company and lists its registered securities, including common stock (BFRI) and warrants (BFRIW) traded on Nasdaq. This Form 8-K does not include numeric financial results; readers must refer to the attached press release for the detailed figures.
Biofrontera Inc. ha diffuso un comunicato stampa che annuncia i risultati finanziari e operativi per i tre e sei mesi chiusi il June 30, 2025. Il comunicato, allegato come Exhibit 99.1, contiene misure finanziarie non-GAAP con riconciliazioni quantitative alle misure GAAP più direttamente comparabili, in conformità alla Regulation G. Si precisa che queste informazioni sono state furnished e non filed, pertanto non sono soggette alla responsabilità ai sensi della Section 18 né vengono automaticamente incorporate per riferimento nelle dichiarazioni di registrazione. Il Form 8-K identifica inoltre la società come emerging growth company e indica i titoli registrati, comprese le azioni ordinarie (BFRI) e i warrant (BFRIW) negoziati sul Nasdaq. Questo Form 8-K non include risultati finanziari numerici; i lettori devono consultare il comunicato allegato per le cifre dettagliate.
Biofrontera Inc. ha difundido un comunicado de prensa que anuncia sus resultados financieros y operativos para los tres y seis meses cerrados el June 30, 2025. El comunicado, adjunto como Exhibit 99.1, incluye medidas financieras no GAAP con conciliaciones cuantitativas frente a las medidas GAAP más directamente comparables, de conformidad con la Regulation G. Se indica expresamente que esta información se está furnished y no filed, por lo que no está sujeta a la responsabilidad prevista en la Section 18 ni se incorpora automáticamente por referencia en las declaraciones de registro. El Form 8-K también identifica al registrante como emerging growth company y enumera sus valores registrados, incluidas las acciones ordinarias (BFRI) y los warrants (BFRIW) cotizados en Nasdaq. Este Form 8-K no contiene resultados financieros numéricos; los lectores deben remitirse al comunicado adjunto para conocer las cifras detalladas.
Biofrontera Inc.는 June 30, 2025로 종료되는 3개월 및 6개월의 재무·영업 실적을 발표하는 보도자료를 제공했습니다. 해당 보도자료는 Exhibit 99.1로 첨부되어 있으며, Regulation G에 따라 가장 직접적으로 비교 가능한 GAAP 수치와의 정량적 조정이 포함된 비-GAAP 재무 지표를 포함하고 있다고 회사는 밝혔습니다. 문서에는 이 정보가 furnished로 제공되었으며 filed된 것이 아니어서 Section 18에 따른 책임 적용 대상이 아니고 등록 서류에 자동으로 참조 포함되지 않는다고 명시되어 있습니다. 이 Form 8-K는 또한 등록기업을 emerging growth company로 식별하고 Nasdaq에서 거래되는 보통주(BFRI) 및 워런트(BFRIW) 등 등록 증권을 기재하고 있습니다. 본 Form 8-K에는 수치화된 재무 결과가 포함되어 있지 않으므로 상세 수치는 첨부된 보도자료를 참조해야 합니다.
Biofrontera Inc. a diffusé un communiqué annonçant ses résultats financiers et opérationnels pour les trois et six mois clos le June 30, 2025. Le communiqué, fourni en tant que Exhibit 99.1, comprend des mesures financières non-GAAP avec des rapprochements quantitatifs vers les mesures GAAP les plus directement comparables, conformément à la Regulation G. Il est précisé expressément que ces informations sont furnished et non filed, et ne sont donc pas soumises à la responsabilité prévue par la Section 18 ni automatiquement incorporées par renvoi dans les déclarations d'enregistrement. Le Form 8-K identifie également l'émetteur comme une emerging growth company et énumère ses titres enregistrés, notamment les actions ordinaires (BFRI) et les warrants (BFRIW) négociés sur le Nasdaq. Ce Form 8-K ne comporte pas de résultats financiers chiffrés ; les lecteurs doivent se référer au communiqué ci-joint pour obtenir les chiffres détaillés.
Biofrontera Inc. hat eine Pressemitteilung veröffentlicht, in der die finanziellen und operativen Ergebnisse für die drei und sechs Monate zum June 30, 2025 bekannt gegeben werden. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und enthält laut Unternehmen Non-GAAP-Finanzkennzahlen mit quantitativen Anpassungen zu den am unmittelbarsten vergleichbaren GAAP-Kennzahlen gemäß Regulation G. Es wird ausdrücklich darauf hingewiesen, dass diese Informationen furnished und nicht filed sind und daher nicht der Haftung nach der Section 18 unterliegen und nicht automatisch durch Verweis in Registrierungsunterlagen aufgenommen werden. Das Form 8-K bezeichnet den Registranten zudem als emerging growth company und listet die registrierten Wertpapiere, darunter Stammaktien (BFRI) und Warrants (BFRIW), die an der Nasdaq gehandelt werden. Dieses Form 8-K enthält keine numerischen Finanzergebnisse; für die detaillierten Zahlen ist die beigefügte Pressemitteilung heranzuziehen.
- Press release furnished reporting financial and operational results for the three- and six-month periods ended June 30, 2025
- Quantitative reconciliations provided linking non-GAAP measures to the most directly comparable GAAP measures in compliance with Regulation G
- Corporate disclosure identifies registered securities (common stock BFRI and warrants BFRIW) and emerging growth company status
- The Form 8-K does not include numeric financial results; detailed figures are contained only in the attached press release (Exhibit 99.1)
- Information is furnished, not filed, which limits Section 18 liability and means the content is not automatically incorporated by reference in registration statements
Insights
TL;DR: Routine earnings disclosure furnished with non-GAAP reconciliations; no numeric results are included in the 8-K itself.
The Company furnished a press release reporting results for the quarter and year-to-date period and provided Regulation G reconciliations for any non-GAAP measures. That practice supports transparency around non-GAAP metrics because the Company supplies quantitative reconciliations to GAAP. Because the information is furnished rather than filed, the Form 8-K limits Section 18 liability. The document lists registered securities including BFRI and BFRIW but contains no financial line items within the Form 8-K body.
TL;DR: Disclosure is procedurally complete and compliant; material content is delivered via an attached press release rather than in-line within the Form 8-K.
The filing meets disclosure norms by furnishing the press release and noting the use of non-GAAP measures with reconciliations under Regulation G. It also clarifies the legal status of the disclosure by stating it is furnished, not filed, which is a standard governance and liability distinction. The Form identifies the company as an emerging growth company and lists its Nasdaq-registered securities. The 8-K itself does not present the underlying numeric results, so material financial detail must be reviewed in Exhibit 99.1.
Biofrontera Inc. ha diffuso un comunicato stampa che annuncia i risultati finanziari e operativi per i tre e sei mesi chiusi il June 30, 2025. Il comunicato, allegato come Exhibit 99.1, contiene misure finanziarie non-GAAP con riconciliazioni quantitative alle misure GAAP più direttamente comparabili, in conformità alla Regulation G. Si precisa che queste informazioni sono state furnished e non filed, pertanto non sono soggette alla responsabilità ai sensi della Section 18 né vengono automaticamente incorporate per riferimento nelle dichiarazioni di registrazione. Il Form 8-K identifica inoltre la società come emerging growth company e indica i titoli registrati, comprese le azioni ordinarie (BFRI) e i warrant (BFRIW) negoziati sul Nasdaq. Questo Form 8-K non include risultati finanziari numerici; i lettori devono consultare il comunicato allegato per le cifre dettagliate.
Biofrontera Inc. ha difundido un comunicado de prensa que anuncia sus resultados financieros y operativos para los tres y seis meses cerrados el June 30, 2025. El comunicado, adjunto como Exhibit 99.1, incluye medidas financieras no GAAP con conciliaciones cuantitativas frente a las medidas GAAP más directamente comparables, de conformidad con la Regulation G. Se indica expresamente que esta información se está furnished y no filed, por lo que no está sujeta a la responsabilidad prevista en la Section 18 ni se incorpora automáticamente por referencia en las declaraciones de registro. El Form 8-K también identifica al registrante como emerging growth company y enumera sus valores registrados, incluidas las acciones ordinarias (BFRI) y los warrants (BFRIW) cotizados en Nasdaq. Este Form 8-K no contiene resultados financieros numéricos; los lectores deben remitirse al comunicado adjunto para conocer las cifras detalladas.
Biofrontera Inc.는 June 30, 2025로 종료되는 3개월 및 6개월의 재무·영업 실적을 발표하는 보도자료를 제공했습니다. 해당 보도자료는 Exhibit 99.1로 첨부되어 있으며, Regulation G에 따라 가장 직접적으로 비교 가능한 GAAP 수치와의 정량적 조정이 포함된 비-GAAP 재무 지표를 포함하고 있다고 회사는 밝혔습니다. 문서에는 이 정보가 furnished로 제공되었으며 filed된 것이 아니어서 Section 18에 따른 책임 적용 대상이 아니고 등록 서류에 자동으로 참조 포함되지 않는다고 명시되어 있습니다. 이 Form 8-K는 또한 등록기업을 emerging growth company로 식별하고 Nasdaq에서 거래되는 보통주(BFRI) 및 워런트(BFRIW) 등 등록 증권을 기재하고 있습니다. 본 Form 8-K에는 수치화된 재무 결과가 포함되어 있지 않으므로 상세 수치는 첨부된 보도자료를 참조해야 합니다.
Biofrontera Inc. a diffusé un communiqué annonçant ses résultats financiers et opérationnels pour les trois et six mois clos le June 30, 2025. Le communiqué, fourni en tant que Exhibit 99.1, comprend des mesures financières non-GAAP avec des rapprochements quantitatifs vers les mesures GAAP les plus directement comparables, conformément à la Regulation G. Il est précisé expressément que ces informations sont furnished et non filed, et ne sont donc pas soumises à la responsabilité prévue par la Section 18 ni automatiquement incorporées par renvoi dans les déclarations d'enregistrement. Le Form 8-K identifie également l'émetteur comme une emerging growth company et énumère ses titres enregistrés, notamment les actions ordinaires (BFRI) et les warrants (BFRIW) négociés sur le Nasdaq. Ce Form 8-K ne comporte pas de résultats financiers chiffrés ; les lecteurs doivent se référer au communiqué ci-joint pour obtenir les chiffres détaillés.
Biofrontera Inc. hat eine Pressemitteilung veröffentlicht, in der die finanziellen und operativen Ergebnisse für die drei und sechs Monate zum June 30, 2025 bekannt gegeben werden. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und enthält laut Unternehmen Non-GAAP-Finanzkennzahlen mit quantitativen Anpassungen zu den am unmittelbarsten vergleichbaren GAAP-Kennzahlen gemäß Regulation G. Es wird ausdrücklich darauf hingewiesen, dass diese Informationen furnished und nicht filed sind und daher nicht der Haftung nach der Section 18 unterliegen und nicht automatisch durch Verweis in Registrierungsunterlagen aufgenommen werden. Das Form 8-K bezeichnet den Registranten zudem als emerging growth company und listet die registrierten Wertpapiere, darunter Stammaktien (BFRI) und Warrants (BFRIW), die an der Nasdaq gehandelt werden. Dieses Form 8-K enthält keine numerischen Finanzergebnisse; für die detaillierten Zahlen ist die beigefügte Pressemitteilung heranzuziehen.
FAQ
What did Biofrontera (BFRI/BFRIW) disclose in this 8-K?
Is the detailed financial data included in the Form 8-K for BFRI?
Does the press release include non-GAAP measures for Biofrontera (BFRI)?
What is the legal status of the information provided in this 8-K?
Which securities of Biofrontera are listed in the filing?
